Monitoring of DNA methylation in ovarian cancer using microarrays.

Czech version

Authors: M. Chmelařová ¹; E. Ruszová ²; J. Laco ³; E. Dvořáková ⁴; J. Smetana ⁵; K. Hrochová ¹; V. Palička ¹
Authors‘ workplace: Ústav klinické biochemie a diagnostiky, Fakultní nemocnice Hradec Králové ¹; Oddělení lékařské genetiky, Fakultní nemocnice Hradec Králové ²; Fingerlandův ústav patologie, Fakultní nemocnice Hradec Králové ³; Porodnická a gynekologická klinika, Fakultní nemocnice Hradec Králové ⁴; Babákova Myelomová skupina, Oddělení patologické fyziologie Masarykova univerzita, Lékařská fakulta ⁵
Published in: Klin. Biochem. Metab., 23 (44), 2015, No. 3, p. 100-104

Overview

Objective:
The aim of this pilot study was whole-genome screening of DNA methylation in ovarian cancer patients. Monitoring of DNA methylation was focused on promoter regions and also on CpG islands.

Design:
Pilot study

Material and methods:
Our study included 6 samples obtained from patients with newly diagnosed ovarian cancer and 6 nonmalignant control samples of ovaries. All samples were analysed using a custom designed methylation microarrays based on the methylated DNA immunoprecipitation.

Results:
Using microarrays designed in collaboration with specialists of the HPST company we found in the tumor tissue tendency to overall DNA hypomethylation. Furthermore we managed to get a set of hypermethylated genes for confirmation analyses.

Conclusion:
DNA methylation changes are considered to be a one of the first changes during carcinogenesis. Due to this fact could be newly identified changes, in case of detection in plasma of ovarian cancer patient, used as screening markers in risk population. Monitoring of DNA methylation could contribute to improve the care of ovarian cancer patients, including possible financial saving due to early diagnosis and possible prediction of response to treatment.

Key words:
ovarian cancer, DNA methylation, microarrays.

Sources

1. Kučera, R., Topolčan, O., Presl, J. et al. Klinický přínos ROMA indexu při diagnostice ovariálního karcinomu. Klin. Biochem. Metab., 2012, 20 (41), p. 248-251.

2. Karlan, B. Y. Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening. Clinical Ovarian Cancer, 2009, 2 (2), p. 83-89.

3. Barton, C. A., Hacker, N. F., Clark, S. J., O’Brien, P. M. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol. Oncol., 2008, 109 (1), p. 129-39.

4. Chmelařová, M., Křepinská, E., Špaček, J. et al. Methylation analysis of tumor suppressor genes in ova-rian cancer using MS-MLPA. Folia Biol (Praha), 2012, 58 (6), p. 246-250.

5. Esteller, M. Epigenetics in Cancer. N Engl. J. Med., 2008, 358 (11), p. 1148-59.

6. Chmelařová, M. and Palička, V. How to analyze DNA methylation? J Turgut. Ozal. Med. Cent., 2013, 20 (3), p. 282-286

7. Croce, C. M. Oncogenes and Cancer. N Engl. J. Med., 2008, 358 (5), p. 502-511.

8. Sherr, C. J. Principles of Tumor Suppression. Cell, 2004, 116(2), p. 235-46.

9. Hulpiau, P., van Roy, F. Molecular evolution of the cadherin superfamily. Int. J. Biochem. Cell. Biol., 2009, 41(2), p. 349-69.

10. Jeanes, A., Gottardi, C. J., Yap, A. S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene, 2008, 27(55), p. 6920-9.

11. Bol, G. M., Suijkerbuijk, K. P., Bart, J., Vooijs, M., van der Wall, E., van Diest, P. J. Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology, 2010, 57 (3), p. 363-370.

12. Chmelařová, M., Křepinská, E., Špaček, J., Laco, J., Nekvindová, J., Palička, V. Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA. Folia Biol. (Praha), 2012, 58 (6), p. 246-50.

13. Yuecheng, Y., Hongmei, L., Xiaoyan, X. Clinical eva-luation of E-cadherin expression and its regulation me-chanism in epithelial ovarian cancer. Clin. Exp. Metastasis. 2006, 23 (1), p. 65-74.

14. Zhang, Q., Hu, G., Yang Q, Dong, R., et al. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol. Onco., 2013, 130 (1), p. 132-9.

15. Heitzer, E., Artl, M., Filipits, M., et al. Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. Mod. Pathol., 2014, 27 (6), p. 906-15.

16. Deng, J., Liang, H., Ying, G., Dong, Q., Zhang, L., Yu, J., Fan, D., Hao, X. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer. J Am. Coll. Surg. 2014 Nov, 219 (5), p. 904-13.

17. Beukers, W., Hercegovac, A., Vermeij, M., et al. Hypermethylation of the polycomb group target gene PCDH7 in bladder tumors from patients of all ages. J Urol., 2013, 190 (1), p. 311-6.

18. Wang, L., Xie, P. G., Lin, Y. L., Ma, J. G., Li, W. P. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy. Med. Sci. Monit., 2014, 20, p. 1363-8.

19. Tang, X., Yin, X., Xiang, T., et al. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Cancer Biomark., 2012-2013, 12 (1), p. 11-9.

20. Yamada, S., Pokutta, S., Drees, F., Weis, W. I., Nelson, W. J. Deconstructing the cadherin-catenin-actin complex. Cell, 2005, 123 (5), p. 889-901.

21. Fanjul-Fernández, M., Quesada, V., Cabanillas, R., et al. Cell-cell adhesion genes CTNNA2 and CTNNA3 are tumour suppressors frequently mutated in laryngeal carcinomas. Nat. Commun., 2013, 4, p. 2531.

22. Wang, T., Chen, Y. H., Hong, H., et al. Increased nucleotide polymorphic changes in the 5’-untranslated region of delta-catenin (CTNND2) gene in prostate cancer. Oncogene, 2009, 28 (4), p. 555-64.

23. Burger, M. J., Tebay, M. A., Keith, P. A., et al. Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int. J. Cancer, 2002, 100 (2), p. 228-37.

24. Xu, D. W., Zhang, G. Q., Wang, Z. W., Xu, X. Y., Liu, T. X. Autophagy in tumorigenesis and cancer treatment. Asian Pac. J. Cancer. Prev., 2015, 16 (6), p. 2167-75.

25. Mathew, R., Karantza-Wadsworth, V., White, E. Role of autophagy in cancer. Nat. Rev. Cancer, 2007, 7 (12), p. 961-7.